Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Bo Liu

Vascular & Interventional Radiology Irvine, CA Medical Doctor

NPI 1801231576 CMS profile 1285799

1000 Fivepoint, Irvine, CA 92618

Open in the dashboard

General payments

$37,515

158 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Bo Liu of Irvine, CA is reported in the CMS Open Payments database as having received $37,515 across 158 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 89th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $20,033 36
2024 General $11,338 46
2023 General $590 15
2022 General $325 5
2021 General $1,870 14
2020 General $442 5
2019 General $2,917 37

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Bo Liu
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Bo Liu were reported at $20,033. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Bo Liu Vascular & Interventional Radiology median Middle half National median
2019 $2,917 $422 $125–$1,555 $163
2020 $442 $200 $68–$652 $114
2021 $1,870 $280 $99–$866 $132
2022 $325 $433 $137–$1,497 $149
2023 $590 $506 $152–$2,019 $160
2024 $11,338 $556 $175–$1,930 $164
2025 $20,033 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sirtex Medical Inc $14,245 31 payments
  2. Inari Medical, Inc. $7,434 24 payments
  3. Penumbra, Inc. $7,362 18 payments
  4. Boston Scientific Corporation $5,833 39 payments
  5. Biocompatibles, Inc. $1,250 3 payments
  6. Cook Medical LLC $222 4 payments
  7. Abbott Laboratories $143 3 payments
  8. Organogenesis Inc. $99 1 payment
  9. W. L. Gore & Associates, Inc. $94 1 payment
  10. Bard Peripheral Vascular, Inc. $92 3 payments
  11. Other $740 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $12,628 33 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $12,199 5 payments
  3. Food and Beverage $9,239 118 payments
  4. Consulting Fee $3,450 2 payments
Products named General payments · program years 2019–2025
  1. SIR-Spheres Microspheres $10,021 21 payments
  2. FLOWTRIEVER CATHETER, S $8,938 33 payments
  3. Indigo System $6,940 15 payments
  4. CT THROMBECTOMY SYSTEM KIT $5,262 9 payments
  5. LAVA LES (Liquid Embolic System) $4,224 10 payments
  6. TheraSphere Y90 Glass Microspheres 10 GBq $2,354 10 payments
  7. THERASPHERE - BIO $1,250 3 payments
  8. OBSIDIO $1,055 6 payments
  9. TheraSphere Y90 Glass Microspheres 7.0 GBq (US Commercial) $876 3 payments
  10. TheraSphere Administration Set $448 4 payments
  11. Other $3,153 60 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 98 billing codes

Paid by Medicare

$71,803

Medicare's payments for the services billed

Medicare patients

300

Average age 72

Services billed

970

149 women, 151 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Cancer 54%
Arthritis 47%
Diabetes 43%
Ischemic heart disease 40%
Chronic kidney disease 36%
Heart failure 24%
Depression 24%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
KEYTRUDA
  • Merck Sharp & Dohme Corporation $29
$29 — —
Vanflyta
  • Daiichi Sankyo Inc. $24
$24 — —
Lenvima
  • Eisai Inc. $22
$22 — —
LYNPARZA
  • Merck Sharp & Dohme Corporation $10
$10 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

158 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record